Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.36 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.36 |
| ▸ | PARP1 | P09874 | 1/20 | 0.36 |
| ▸ | PARP10 | Q53GL7 | 1/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 2/20 | 0.30 |
| ▸ | METAP1 | P53582 | 1/20 | 0.30 |
| ▸ | MAOA | P21397 | 1/20 | 0.30 |
| ▸ | MAOB | P27338 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2675846 | 0.71 | TDP1 (0.39) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL2674737 | 0.71 | PARP10 (0.36) | PARP10 | |
| SCHEMBL28569205 | 0.67 | PARP10 (0.43) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL9483990 | 0.67 | PARP10 (0.43) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL27710326 | 0.67 | PARP10 (0.44) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL29009009 | 0.67 | CHEK2 (0.33) | METAP1 | |
| SCHEMBL598138 | 0.65 | TDP1 (0.61) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL769170 | 0.64 | PARP10 (0.40) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| SCHEMBL6097069 | 0.64 | PARP10 (0.40) | TDP1L3MBTL1PARP1PARP10METAP1 | |
| Acetic Acid SCHEMBL9127778 | 0.64 | TDP1 (0.41) | TDP1L3MBTL1PARP1PARP10 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8173696-B2 | Inhibitors of cysteine proteases and methods of use thereof | BAYLOR UNIVERSITY (US) | 2012-05-08 | — | — | US | disclosed |
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | BAYLOR UNIVERSITY (US) | 2009-03-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090076076-A1 | INHIBITORS OF CYSTEINE PROTEASES AND METHODS OF USE THEREOF | CTSB, CTSS, CTSZ | TDP1 3302/4885L3MBTL1 340/4885PARP1 3368/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.